Astrazeneca Ab

Cancer Research Technology Limited

Dizal (jiangsu) Pharmaceutical Co., Ltd.

Dizal Pharmaceutical Co., Limited

Frederick Woolf Goldberg

Attilla Kuan Tsuei Ting

Jason Grant Kettle

Maurice Raymond Verschoyle Finlay

Graeme Richard Robb

Bernard Barlaam

Dedong Wu

Sharanjeet Kaur Bagal

Gillian McGregor Lamont

David Buttar

Qibin Su

James Michael Smith

Andrew John Eatherton

Tyler Grebe

Sudhir Mahadeo Hande

Neil Patrick Grimster

Paul David Kemmitt

Avipsa Ghosh

Doyle Joseph Cassar

Michael Steven Bodnarchuk

Jason Shields

Reem Telmesani

James Sheppeck

Kun Song

Phillip Lichtor

Martin Richard Howard

Shaun Michael Fillery

Scott Gibson Lamont

James Lyman Feron

Kathryn Giblin

Sten Nilsson Lill

Lucas Morrill

Randolph Escobar

Anthony Metrano

Robert Evans Ziegler

Amber Balazs

Ye Wu

Adelphe Mfuh

Li Sha

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

2,6,9-trisubstituted purines

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R, A, Aand Ahave any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

Purinone compounds and their use in treating cancer

The invention concerns compounds of Formula (I):

Triazolopyrimidine compounds and their use in treating cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Rand Rhave any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

Amino-triazolopyridine compounds and their use in treating cancer

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Tetracyclic heteroaryl compounds

The invention concerns compounds of Formula (I): 

Chemical compounds

Growing community of inventors

Cambridge, United Kingdom

Frederick Woolf Goldberg